Directors' Report
To
The Members,
Your Directors are pleased to present their Report together with the Audited Standalone
and Consolidated Financial Statements for the financial year ended March 31,2024.
OVERVIEW
Jubilant Ingrevia Limited (the 'Company' or Jubilant Ingrevia') is a global integrated
Life Science products and Innovative Solutions provider serving Pharmaceutical, Nutrition,
Agrochemical, Consumer and Industrial customers with customised products and solutions
that are innovative, cost-effective and conforming to excellent quality standards.
The Company offers a broad portfolio of high quality ingredients that find application
in a wide range of industries. The Company has over 2,300 employees and serves 1,500+
customers in 63 countries across the world. The Company's portfolio also extends to custom
research and manufacturing for pharmaceutical and agrochemical customers on an exclusive
basis.
The Company is a Responsible Care certified Company, driven by the motive to add value
to millions of lives through innovations and cutting-edge technology. As a leader in key
products that the Company manufactures, it takes pride in being a partner of choice for
its valued customers.
RESULTS OF OPERATIONS AND STATE OF COMPANY'S AFFAIRS
The financial performance of the Company for FY 2024 is summarised below:
|
|
|
|
(Rs./million) |
|
Standalone |
Consolidated |
PARTICULARS |
Year ended March 31, 2024 |
Year ended March 31, 2023 |
Year ended March 31, 2024 |
Year ended March 31, 2023 |
Revenue from Operations |
39,872 |
45,596 |
41,358 |
47,727 |
Total operating expenditure |
35,843 |
40,651 |
37,147 |
42,256 |
Earnings before Interest, Taxes, Depreciation and Amortisation expense (EBITDA)
(before other income) |
4,029 |
4,945 |
4,211 |
5,471 |
Other income |
355 |
310 |
353 |
334 |
EBITDA |
4,384 |
5,255 |
4,564 |
5,805 |
Depreciation and amortisation expense |
1,331 |
1,197 |
1,362 |
1,222 |
Finance costs |
663 |
382 |
526 |
216 |
Exceptional items |
- |
- |
- |
- |
Share of profit/(loss) of an associate |
- |
- |
- |
- |
Profit before tax |
2,390 |
3,676 |
2,676 |
4,367 |
Total tax expense |
766 |
1,142 |
847 |
1,292 |
Profit after tax (PAT) |
1,624 |
2,534 |
1,829 |
3,075 |
Attributable to: |
|
|
|
|
- Owners of the company |
1,624 |
2,534 |
1,829 |
3,075 |
- Non-controlling interests |
- |
- |
- |
- |
Other comprehensive income |
(10) |
(9) |
35 |
24 |
Total comprehensive income for the year |
1,614 |
2,525 |
1,864 |
3,099 |
Balance in Retained earnings at the beginning of the year |
8,291 |
6,561 |
11,577 |
9,310 |
Profit for the year (attributable to owners of the Company) |
1,624 |
2,534 |
1,829 |
3,075 |
Re-measurement of defined benefit obligations |
(10) |
(9) |
(11) |
(13) |
Dividend |
(796) |
(796) |
(790) |
(795) |
Issue of equity shares by Trust on exercise of stock options |
12 |
1 |
2 |
- |
Balance in Retained earnings at the end of the year |
9,121 |
8,291 |
12,607 |
11,577 |
(i) Standalone Financials Revenue from Operations
In FY 2024, on a standalone basis, your Company's total revenue from operations
Rs.39,872 million as against Rs.45,596 million in FY 2023.
EBITDA
For FY 2024, EBITDA stood at Rs.4,384 million with EBITDA margins at 11% as against
EBITDA of Rs.5,255 million with EBITDA margins at 12% in FY 2023.
Profit after tax ('PAT')
PAT was H 1,624 million in FY 2024 as against Rs.2,534 million in FY 2023.
(ii) Consolidated Financials
The consolidated financial statements, prepared in accordance with the provisions of
the Companies Act, 2013 (the 'Act'), the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') and
Indian Accounting Standards (Ind-AS) as per the Companies (Indian Accounting Standards)
Rules, 2015 notified under Section 133 of the Act form part of the Annual Report.
Performance Review
On a consolidated basis, your Company reported revenue from operations Rs.41,358
million in FY 2024 as against Rs.47,727 million in FY 2023. EBITDA was Rs.4,564 million in
FY 2024 as against Rs.5,805 million in FY 2023 and PAT was Rs.1,829 million in FY 2024 as
against Rs.3,075 million in FY 2023.
During FY 2024, the segment revenue from the Speciality Chemicals was Rs.15,855 million
as against Rs.17,983 million in FY 2023, Nutrition and Health Solutions was Rs.6,800
million in FY 2023 as against Rs.5,512 million in FY 2024 and Chemicals Intermediates
revenue was Rs.18,703 million in FY 2024 as against Rs.24,232 million in FY 2023. The
overall EBITDA in FY 2024 was Rs.4,564 million as against Rs.5,805 million in FY 2023
translating to EBITDA margin of 11% in FY 2024 as against 12% in FY 2023.
Further, the net profit attributable to the owners of the Company was Rs.1,829 million
in FY 2024 as against Rs.3,075 million in FY 2023 and the basic EPS stood at Rs.11.56
(Diluted Rs.11.55) in FY 2024 as against Rs.19.34 (Diluted Rs.19.33) in FY 2023.
A detailed note on Performance Review is given under 'Management Discussion and
Analysis Report.
PARTNERED WITH O2 RENEWABLE ENERGY XVIII PRIVATE LIMITED ('O2 ENERGY') FOR ACQUISITION
OF UPTO 28% STAKE
During FY 2024, the Company has partnered with O2 Renewable Energy XVIII Private
Limited, a group company of O2 Power SG PTE. Ltd., Singapore, a leading renewable energy
developer for acquisition of upto 28% stake for purchase of renewable energy power
generated from the Captive Generating Plant. This partnership marks a significant step for
the Company towards establishing renewable energy power generation using hybrid open
excess through solar and wind sources. The Company aims to access renewable energy through
a captive arrangement, fulfilling the Company's power requirements and meeting its
increasing demand from green energy to power its manufacturing facilities at Gajraula,
Uttar Pradesh and Savli, Gujarat. This represents an important milestone in the Company's
sustainability journey by reducing dependence on non-renewable energy sources and reducing
its carbon footprint.
ACQUISITION OF SHARES OF FORUM I AVIATION PRIVATE LIMITED ('FAPL')
During FY 2024, Jubilant Infrastructure Limited ('JIL'), wholly owned subsidiary of the
Company has purchased 6.67% equity Share in FAPL from MAX ATEEV Limited. Post-acquisition,
JIL holds 9.12% equity shares in FAPL.
TRANSFER TO RESERVES
During the year under review, no amount was transferred to general reserves by the
Company.
DIVIDEND
During the year, the Board of Directors of the Company declared an interim dividend of
Rs.2.50 (250%) per equity share at its Board Meeting held on January 30, 2024 on 159.28
million equity shares of Rs.1 each. The Directors are pleased to recommend a final
dividend of Rs.2.50 (250%) per equity share of Rs.1 each, which if approved at the ensuing
Annual General Meeting ('AGM'), will be paid to all those Equity Shareholders of the
Company whose names appear in the Register of Members and whose names appear as beneficial
owners as per the beneficiary list furnished for the purpose by National Securities
Depository Limited ('NSDL') and Central Depository Services (India) Limited ('CDSL') as on
record date i.e. Friday, August 2, 2024. The total dividend for the year would be Rs.5
(500%) per equity share of face value of Rs.1 each aggregating to Rs.796 million (Rupees
seven hundred ninety six million only).
Your Company believes in maintaining a fair balance between cash retention and dividend
distribution. Cash retention is required to finance acquisitions and future growth and
also as a mean to meet any unforeseen contingencies. Pursuant to Regulation 43A of the
Listing Regulations the Company has formulated its Dividend Distribution Policy which
specifies the financial parameters, internal and external factors that are to be
considered by Board while declaring a dividend. Dividend Distribution Policy is uploaded
on the website of the Company which can be accessed at https://www.jubilantingrevia.com/
investors/corporate-governance/policies-and-codes/dividend- distribution-policy.
CHANGE IN NATURE OF BUSINESS
During FY 2024, there was no change in the nature of Company's business.
CAPITAL STRUCTURE
(a) Share Capital
During the year, there was no change in the authorised share capital of the Company. As
on March 31, 2024, the subscribed, issued and paid-up share capital of the Company stood
at Rs.159.28 million comprising 159.28 million equity shares of Rs.1 each.
The Company has not issued any equity shares with differential rights, sweat equity
shares or bonus shares. The Company has only one class of equity shares with face value of
Rs.1 each, ranking pari-passu.
Further, during FY 2024, the Company has not raised the funds through preferential
allotment or qualified institutions placements.
(b) Employees Stock Option Plan and General Employee Benefits Scheme
The Company has 'Jubilant Ingrevia Employees Stock Option Plan 2021' ('ESOP-2021') and
a General Employee Benefits Scheme namely Jubilant Ingrevia General Employee Benefits
Scheme-2021' ('JIGEBS-2021') for the employees of the Company and its subsidiary
companies. ESOP-2021 and JIGEBS-2021 are in compliance with the SEBI (Share Based Employee
Benefits and Sweat Equity) Regulations, 2021 ('SEBI ESOP Regulations').
During the year, the below stated material changes were made in ESOP-2021.
The maximum number of Shares that may be granted pursuant to exercise of all
Options granted to the Participants were increased from 15,00,000 (Fifteen Lac) Shares to
20,00,000 (Twenty Lac) Shares.
The maximum number of Options that may be granted to an Eligible Employee was
amended from (i) 1,25,000 (One Lac Twenty Five Thousand) per annum; and (ii) 6,50,000 (Six
Lac Fifty Thousand) in aggregate to 10,00,000 (Ten Lac) in aggregate.
The details of ESOP-2021 and JIGEBS-2021 as required under the SEBI ESOP Regulations
have been placed on the website of the Company and web-link of the same is https://www.
iubilantingrevia.com/investors/financials/annual-reports.
SUBSIDIARIES, ASSOCIATE AND JOINT VENTURE COMPANIES
The highlights of performance of subsidiaries and associates companies and their
contribution to the overall performance of the Company during the period under report is
provided in note no. 46 to the consolidated financial statements. The Company does not
have any joint venture. A separate statement containing the salient features of financial
statements of subsidiaries and associates of the Company in the prescribed form AOC-1
forms a part of consolidated financial statements, in compliance with Section 129(3) and
other applicable provisions, if any, of the Act read with the rules issued thereunder.
Brief particulars of the subsidiaries of the Company on a standalone basis are given
below:
1. Jubilant Infrastructure Limited ('JIL')
JIL, a wholly-owned subsidiary of the Company has developed a sector specific Special
Economic Zone ('SEZ') for chemicals in Gujarat with the best in class infrastructure
facilities and utility Plants like boiler, effluent treatment, incinerator, roads and DM
water. During the year construction of a captive Power Plant of 10MW with 98TPH high
pressure boiler has commenced. This will facilitate to meet out the requirement of steam
& power of JIL, Jubilant Agro Sciences Limited ('JASL') and Jubilant Ingrevia at
optimised cost.
JIL has three units of Jubilant Ingrevia and one unit of JASL in SEZ.
Total income of JIL during FY 2024 was Rs.2,117 million as against Rs.1,763 million for
FY 2023.
2. Jubilant Agro Sciences Limited (formerly Jubilant Crop Protection Limited)
JASL, a wholly owned subsidiary of the Company, has set up its Crop protection
chemicals and Agro active/ intermediates manufacturing facilities in Bharuch.
JASL commenced March-24 operations during the year. Total income of JASL during FY 2024
was Rs.30 million.
3. Jubilant Life Sciences (USA) Inc. ('JLS-USA')
JLS-USA, incorporated in Delaware-USA, is a wholly-owned subsidiary of the Company. It
undertakes sales, distribution and business transactions of the Company's products in
America. Total income of JLS-USA during FY 2024 was Rs.2,404 million as against Rs.1,803
million for FY 2023.
4. Jubilant Life Sciences International Pte. Limited ('JLSIL')
JLSIL, incorporated in Singapore, is a wholly-owned subsidiary of the Company. Total
income of JLSIL during FY 2024 was Rs.65 million as against Rs.62 million for FY 2023.
5. Jubilant Life Sciences (Shanghai) Limited ('JLS-Shanghai')
JLS-Shanghai is a wholly-owned subsidiary of the Company. It undertakes sales,
distribution and business transactions of the Company's products in China. Total income of
JLS-Shanghai during FY 2024 was Rs.901 million as against H 1,112 million for FY 2023.
MATERIAL SUBSIDIARY
Jubilant Life Sciences NV ('JLS NV')
JLS NV, incorporated in Belgium, is a wholly-owned subsidiary of the Company. It
undertakes sales, distribution and business transactions of the Company's products in the
European markets. Total income of JLS NV during FY 2024 was Rs.6,030 million as
against Rs.6,792 million for FY 2023. As on March 31, 2024, JLS NV was material
subsidiary of the Company as per the parameters laid down under the Listing Regulations,
as amended. The Company's policy on material subsidiaries can be accessed at https://www.
iubilantingrevia.com/investors/corporate-governance/policies-
and-codes/policy-for-determining-material-subsidiaries.
Details of material subsidiaries including the date and place of incorporation and the
name and date of appointment of the statutory auditors of JLS NV is stated below:
S. No. |
Name |
Date of Incorporation |
Place of Incorporation |
Name of Statutory Auditors |
Date of Appointment of Statutory Auditor |
1 |
|
|
|
|
|
ASSOCIATES
1. Mister Veg Foods Private Limited ('MVFPL')
Your Company holds 37.98% of equity share capital of MVFPL on a fully diluted basis
through conversion of existing Convertible Preference shares into Equity Shares as well as
through subscription of Equity Shares on rights basis.
MVFPL is engaged in the development and manufacturing of plant-based Meat Analogues and
mainly markets its products in India. This is a growing segment globally with potential
for scale up.
2. AMP Energy Green Fifteen Private Limited ('AMP Energy')
Your Company holds 26% equity share capital of AMP Energy. The Company has entered into
a Power Purchase Agreement ('PPA') with AMP Energy to procure 100% of the output of solar
energy produced for next 20 years as per the rates negotiated in the agreement. During the
year the Company sourced the Power as per the PPA.
STATUTORY AUDITORS
In terms of provisions of Section 139 of the Act and the Rules made thereunder, the
Shareholders of the Company at its first Annual General Meeting held on December 1, 2020,
approved the appointment of M/s. Walker Chandiok & Co. LLP, Chartered Accountants (FRN
001076N/N500013) as Statutory Auditors of the Company for a term of 5 years. Accordingly,
they hold the office till the conclusion of the 6th Annual General Meeting
('AGM') of the Company to be held in the year 2025.
The Auditors' Report for FY 2024 do not contain any qualification, reservation, adverse
remark or disclaimer.
REPORTING OF FRAUDS BY AUDITORS
During the year, there were no instances of frauds reported by Auditors under
Section143 (12) of the Act. Further, no case of Fraud has been reported to the Management
from any other sources.
COST AUDIT
In terms of Section 134 of the Act read with Rule 8 of the Companies (Accounts) Rules,
2014, the cost accounts and records are prepared and maintained by the Company pursuant to
the provisions of Section 148(1) of the Act.
Pursuant to Section 148 of the Act read with the Companies (Cost Records and Audit)
Rules, 2014, the Central Government has prescribed audit of cost records for certain
products. Accordingly, the Company carries out cost audit of its products. The Cost Audit
Report for FY 2023 was filed with Ministry of Corporate Affairs.
Based on the recommendations of the Audit Committee, the Board of Directors have
re-appointed M/s J. K. Kabra & Co., Cost Accountants as Cost Auditors of the Company
to conduct cost audit for FY 2025.
The Board of Directors on the recommendation of the Audit Committee have approved the
remuneration payable to Cost Auditors in terms of Section 148 of the Act and rules made
thereunder. Members are requested to consider the ratification of remuneration payable to
M/s J.K. Kabra & Co., Cost Accountants for FY 2025.
SECRETARIAL AUDIT
The Board has appointed M/s Sanjay Grover & Associates, Company Secretaries to
conduct Secretarial Audit in accordance with the provisions of Section 204 of the Act and
the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 for FY
2024. The Secretarial Audit Report for FY 2024 has been obtained and does not contain any
qualification, which requires any comments from the Board. The Secretarial Audit Report
for FY 2024 is annexed to this report as Annexure -1.
The Company has also obtained a Secretarial Compliance Report from M/s Sanjay Grover
& Associates, Company Secretaries confirming compliances with the provisions of the
applicable Listing Regulations, Circulars and Guidelines for FY 2024. The Secretarial
Compliance Report has been duly filed with the Stock Exchanges in Compliance with the
Listing Regulations.
DIRECTORS AND KEY MANAGERIAL PERSONNEL
During the year, Mr. Hari S. Bhartia, Co-Chairman was re-designated as Co-Chairman and
Whole-Time Director of the Company effective from June 1,2023.
Mr. Rajesh Kumar Srivastava, CEO and Managing Director superannuated from the services
of the Company effective from the close of business hours of September 30, 2023 and Mr.
Deepak Jain was appointed as CEO and Managing Director of the Company effective from
October 1,2023 for a term of five years.
Mr. Chandan Singh Sengar was appointed as Whole - Time Director designated as Co-CEO
and Whole-Time Director on the Board of the Company effective from May 16, 2023 and Mr.
Anil Khubchandani resigned as Co-CEO and Whole-Time Director from the Board of the Company
effective from the close of business hours of May 19, 2023.
Re-designation of Co-Chairman, appointment of CEO and Managing Director & Co-CEO
and Whole-Time Director were recommended to the Board by the Nomination, Remuneration and
Compensation Committee ('NRC') and approved by the shareholders.
In terms of the applicable provisions of the Act and the Articles of Association of the
Company, Mr. Shyam S. Bhartia and Mr. Priyavrat Bhartia, are liable to retire by rotation
at the ensuing AGM and being eligible have offered their candidature for re-appointment.
The re-appointment of directors liable to retire by rotation have been recommended to the
Board by NRC. Brief resume and other details of Mr. Shyam S. Bhartia and Mr. Priyavrat
Bhartia have been furnished in the Annexure to the notice of AGM.
Mrs. Sudha Pillai and Mr. Sushil Kumar Roongta were appointed as Independent Directors
for a term of five consecutive years commencing from February 6, 2021 upto February 5,
2026. They shall attain the age of 75 years during their tenure as Independent Directors.
Being eligible in terms of the Companies Act, 2013 and the Listing Regulations, the Board
on recommendation of the NRC has approved their continuation on the Board of the Company
for remaining tenure as Independent Directors, subject to passing of special resolution by
the shareholders in accordance with Regulation 17(1A) of the Listing Regulations. Brief
resume and other details of Mrs. Sudha Pillai and Mr. Sushil Kumar Roongta have been
furnished in the Annexure to the notice of AGM.
In compliance with Section 150 of the Companies Act, 2013 read with Rule 6 of the
Companies (Appointment and Qualification of Directors) Rules, 2014, the details of all the
Independent Directors have been registered with the databank maintained by the Indian
Institute of Corporate Affairs (IICA). Further, all the Independent Directors have passed
the online proficiency self-assessment test conducted by IICA except those who have been
exempted by the Act.
In the opinion of the Board, the Independent Directors of the Company are persons of
high repute, integrity and possesses the relevant expertise and experience in the
respective fields. They fulfil the conditions specified in the Act, Rules made thereunder
and Listing Regulations and are independent of the management.
None of the Directors on the Board of the Company has been debarred or disqualified
from being appointed or continuing as directors of companies by the Securities and
Exchange Board of India, Ministry of Corporate Affairs or any other statutory authority.
Key Managerial Personnel
Pursuant to the provisions of Section 203 of the Act, Mr. Deepak Jain, CEO and Managing
Director, Mr. Prakash Chandra Bisht, President and Chief Financial Officer & Ms.
Deepanjali Gulati, Company Secretary and Compliance Officer are the Key Managerial
Personnel of the Company as on March 31,2024.
MEETINGS OF THE BOARD
During FY 2024, six meetings of the Board of Directors of the Company were held. For
details of these Board meetings, please refer to the section on Corporate Governance of
this annual report.
COMPOSITION OF AUDIT COMMITTEE
As on date, the Audit Committee comprises Mr. Sushil Kumar Roongta, Chairman, Mr. Arun
Seth, Mr. Pradeep Banerjee, Mr. Siraj Azmat Chaudhry, Ms. Ameeta Chatterjee and Mr. Arjun
Shanker Bhartia. The Board has accepted all the recommendations made by the Audit
Committee.
DECLARATION OF INDEPENDENT DIRECTORS
All Independent Directors have given declaration that they meet the criteria of
independence as provided under Section 149 of the Act and Regulation 16 of the Listing
Regulations.
The Independent Directors have also complied with the Code for Independent Directors as
per Schedule IV of the Act. None of the Directors of the Company are disqualified for
being appointed as Directors as specified under Section 164(2) of the Act read with Rule
14(1) of the Companies (Appointment and Qualification of Directors) Rules, 2014.
APPOINTMENT AND REMUNERATION POLICY
The Company has implemented Appointment and Remuneration Policy pursuant to the
provisions of Section 178 of the Act and Regulation 19 read with Part D of Schedule II to
the Listing Regulations. Salient features of the Policy and other details have been
disclosed in the Corporate Governance Report attached to this Report. The Policy is
available at the weblink https://www.
iubilantingrevia.com/investors/corporate-governance/policies-
and-codes/appointment-and-remuneration-policy.
ANNUAL PERFORMANCE EVALUATION OF THE BOARD
A statement on annual evaluation of the performance of the Board, its Committees and of
individual Directors forms part of the Corporate Governance Report attached to this
Report.
DIRECTORS' RESPONSIBILITY STATEMENT
Your Directors, based on the representation received from the management, confirm that:
(i) in the preparation of the annual accounts, the applicable accounting standards have
been followed along with proper explanation relating to material departures;
(ii) the Directors have selected such accounting policies and applied them consistently
and made judgments and estimates that are reasonable and prudent so as to give a true and
fair view of the state of affairs of the Company as on March 31,2024 and of the profits of
the Company for the year ended March 31, 2024;
(iii) the Directors have taken proper and sufficient care for the maintenance of
adequate accounting records in accordance with the provisions of the Act for safeguarding
the assets of the Company and for preventing and detecting fraud and other irregularities;
(iv) the Directors have prepared the annual accounts on a going concern basis;
(v) the Directors have laid down internal financial controls to be followed by the
Company and that such internal financial controls are adequate and are operating
effectively.
Based on the framework of internal financial controls including the Controls Manager
for financial reporting and compliance systems established and maintained by the Company,
work performed by the Internal, Statutory and Secretarial Auditors and the reviews
performed by the management and the relevant Board committees, including the Audit
Committee, the Board is of the opinion that the Company's internal financial controls were
adequate and effective during FY 2024; and
(vi) the Directors have devised proper systems to ensure compliance with the provisions
of all applicable laws and that such systems are adequate and operating effectively.
CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO
Information relating to Conservation of Energy, Technology Absorption and Foreign
Exchange Earnings and Outgo required to be disclosed pursuant to Section 134 of the Act
read with the Companies (Accounts) Rules, 2014 is given as Annexure-2 and forms
part of this Report.
INFORMATION REGARDING EMPLOYEES, AND RELATED DISCLSOURES
The statement of Disclosure of Remuneration under Section 197 of the Act and Rule 5(1)
of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014
('Rules'), is annexed as Annexure - 3 and forms an integral part of this Report.
The statement containing particulars of employees, as required under Section 197 of the
Act, read with Rule 5(2) and
Rule 5(3) of the Rules, is provided in a separate annexure forming part of this Report.
However, in terms of the provisions of Section 136 of the Act, the annual report is being
sent to the members of the Company, excluding the said annexure. The said annexure is
available for inspection by the shareholders at the Registered Office of the Company
during working hours of the Company [(i.e., on Monday to Friday between 11:00am to
5:00pm)]. Any shareholder interested in obtaining a copy of the said annexure may write to
the Company Secretary of the Company or send an email at the following email address:
investors.ingrevia@iubl.com.
RISK MANAGEMENT AND INTERNAL CONTROL SYSTEMS
Risk-taking is an inherent trait of any enterprise. However, if risks are not properly
managed and controlled, they can affect the Company's ability to attain its objectives.
The Board of Directors constituted a Risk Management Committee ('RMC') to formulate a
detailed risk management policy and oversee risk management processes & systems. The
Risk Management Committee acts as a governing body to monitor the effectiveness of the
risk management framework.
The Board, Audit Committee, Risk Management Committee and Senior Management play a
critical role in fostering a strong risk culture of the Company by identifying the risks
impacting the Company's business and documenting the process of identification,
evaluation, prioritisation, mitigation, monitoring and communication of risk as a part of
the risk management policy. The Company's commitment to sound governance extends beyond
policy. The Company has established a foundation of well-defined and communicated
corporate values. Clear lines of accountability, appropriate delegation of authority, and
a comprehensive set of processes and guidelines ensure transparency and responsible
decision-making across the organisation. The Company's growth strategy thrives on
calculated risk-taking and to ensure long-term success, the Company prioritise the
implementation of robust risk management practices and comprehensive internal financial
controls. These frameworks serve as the foundation for Company's operations, guiding
decision-making and safeguarding the ability to achieve established strategic obiectives.
There exists a well-designed risk management framework and the same is reviewed by the
Board on a periodic basis. Some of the key risks identified in various businesses of the
Company are specified below:
i. Health & Safety
ii. Loss of market share, increase in competitiveness and margin volatility due to high
dependency on commodity segment products
iii. Delay in Growth Projects/ Capex
iv. Geo-Economic, Geo-Political and Macro-Economic instability (disruption in Supply
Chain)
v. Human Resource
vi. Regulatory & Compliances
vii. Cyber Threats
viii. ESG & Sustainability
ix. Individual & Group Activism
x. Research & Development/ New Product Development
xi. Failure to Digitalise
The Company promotes strong ethical values and high levels of integrity in all its
activities, which in itself is a significant risk mitigator. With the growth strategy in
place, risk management holds the key to the success of the Company's continued competitive
advantage and achieving the Company's desired business objectives.
Implementation of Internal Financial Controls
The Company's internal control systems are effective and robust, ensuring that there is
efficient use and protection of resources and compliance with policies, procedures,
financial reporting and statutory requirements. There are well-documented guidelines,
procedures and processes, integral to the overall governance, laws and regulations.
To compete globally, stringent Corporate Governance and financial control over
operations is essential for the Company. To ensure a robust Internal Financial Controls
framework, the Company has worked on three lines of defence strategy which is as under:
i. Build internal controls into operating processes - To this end, the Company
has ensured that detailed Delegation of Authority and Standard Operating Procedures (SOPs)
for the processes are followed, financial decision making is done through Committees, IT
controls are built into the processes, segregation of duties is done, strong budgetary
control framework exists, the entity level controls including Code of Conduct,
Ombudsperson Office, etc. are established. For better governance, these operational
controls have been implemented through Enterprise Resource Planning (ERP) and other IT
applications.
ii. Create an efficient review mechanism - The Company has created a review
mechanism under which all the businesses are reviewed for performance once in a month and
functions are reviewed on a monthly/quarterly basis by the CEO and Managing Director.
Additionally, a robust quarterly controls self-assessment (CSA) process is in place which
enables process owners to perform self-assessment against the Risk and Control Matrices
(RACM). The CSA process enables the Company to monitor the adequacy and effectiveness of
the internal control environment.
Further, statutory compliances are monitored through online tool 'Conformity.
Amendments or new statutory requirements are also updated on a regular basis in the tool
for effective tracking and adherence. This reinforces the Company's commitment to adopt
best corporate governance practices.
iii. Independent assurance - The Company has appointed a Big Four firm as
internal auditors to perform systematic independent audit of every aspect of the business
to provide independent assurance on the effectiveness of the internal controls and
highlight the gaps for continuous improvement. The Audit Committee reviews observations
reported by Internal Auditors and implementation status of audit recommendations &
improvements.
Additionally, the Statutory Auditors audited financial statements of the Company
included in this Annual Report and have issued an Independent report on the Company's
internal control over financial reporting (as defined in Section 143 of the Act). The
Audit Committee acts as a governing body to monitor the effectiveness of the Internal
Financial Controls framework.
To improve the controls in operations, the Company has established, for each line of
business, the concept of financial decision making through operational committees. The
entire purchase, credit control and capital expenditure decisions are taken jointly in
committees.
A detailed note on Internal Control Systems and Risk Management is given under 'Management
Discussion and Analysis Report'.
CERTIFICATIONS
Responsible Care & Integrated Management System
The Company demonstrates its commitment towards Environment, Health, Safety and
Security of its Employees, Work places, Surroundings including Communities by implementing
Responsible Care RC 14001:2015 under American Chemistry Council's (ACC) Responsible Care?
program. The Company is certified by DNV for RC 14001:2015 (Responsible Care?14001:2015)
system at its corporate office in Noida and Manufacturing sites in Gajraula, Uttar
Pradesh, Bharuch in Gujarat and Nira in Maharashtra.
The Company's Corporate Office in Noida and Manufacturing facilities at Gajraula,
Bharuch, Nira, Savli & Ambernath have been awarded Responsible Care Logo (RC Logo) by
Indian Chemistry Council (ICC).
Responsible Care initiative encompasses comprehensive environmental management system,
occupational health and safety, product stewardship, security, community outreach and
transportation safety and aims at achieving and sustaining high standards of performance.
Gajraula, Nira, Bharuch and Savli Manufacturing facilities are certified under
Integrated Management System program for ISO 9001:2015 (Quality Management System), ISO
14001:2015 (Environmental Management System) and ISO 45001:2018 (Occupational Health and
Safety Management system).
The Corporate Office in Noida and Branch offices Mumbai and Hyderabad are certified for
Quality Management System ISO 9001:2015.
The Corporate Office in Noida is certified for Information Security Management System
ISO/IEC 27001:2013.
Gajraula manufacturing facility has been certified for the American
Chemistry Council Technical Specification standard RC 14001:2015, Energy Management System
(ISO 50001:2018), Food Safety System Certification Standard (FSSC 22000 Version 5.1), and
the Certification Scheme for Food Safety
Management System (ISO 22000:2018) for FSSAI products. Company's quality control
laboratory has been accredited by National Accreditation Board for Testing and Calibration
Laboratories (NABL) for chemical testing in accordance with the ISO/IEC 17025:2017. This
manufacturing facility has Kosher and Halal certifications for several products.
Bharuch manufacturing facility has been certified for the American Chemistry
Council Technical Specification standard RC 14001:2015 and Energy Management System (ISO
50001:2018). The Niacinamide manufacturing facility has been certified for WHO GMP, Food
Safety Management System Certification Standard (FSSC 22000 Version 5.1) for the
manufacturing and sale of Niacinamide for food application. The Company has also got GMP
certification by SGS, GMP in compliance with FAMI-QS code (version 6) for the production
of relevant food/feed ingredients and other ingredients. The Company's quality control
laboratory has been accredited by the National Accreditation Board for Testing and
Calibration Laboratories (NABL) for chemical testing in accordance with the ISO/IEC
17025:2017. The facility is certified by Kosher, Halal- India, Halal-Indonesia, and FSSAI.
Nira manufacturing facility has been certified for American Chemistry Council
Technical Specification standard RC 14001:2015. This facility has been certified for Food
Safety System Certification Standard (FSSC 22000 Version 5.1) and Certification Scheme for
Food Safety Management System (ISO 22000:2018) for relevant food applications. This
facility is certified by Kosher, Halal-India, and FSSAI.
Savli manufacturing facility has been certified for Feed Safety Management
System including GMP in compliance with FAMI- QS code (version 6) to produce speciality
feed ingredients.
Ambernath manufacturing facility is ISO 9001:2015 certified for Quality
Management Systems.
HUMAN RESOURCES
At the heart of the Company is the commitment to foster an "Employee First"
culture, driven by its values of caring, sharing, and growing.
The Company has set up mechanisms to receive feedback from employees at various points
during their tenure. This allows the Company to identify areas of strength for further
reinforcement and areas of concern to be addressed with agility. In partnership with
Willis Towers Watson, the Company has introduced the 'Jubivoice Employee Experience
Survey) which garnered a sustainable engagement score of 94%. This is a testament to the
Company's commitment to fostering a workplace where every individual feels valued and
supported.
There is a continuous investment in enhancing the employee experience. The Company has
been comprehensively addressing the four elements of wellbeing: physical, mental, social,
and financial. The Company enables this through Employee Assistance Programs (EAP),
delivered by experts and industry professionals. The Company strives to provide its
employees with the tools and resources they need to thrive personally and professionally.
The Company recognises that its greatest asset in achieving business success is its
talented workforce, and ensuring that they're equipped for the challenges ahead, the
Company has fostered a culture of continuous learning and development. Through structured
classroom training and a cutting-edge digital learning platform, the Company provides its
employees with the skill-set, mind-set, and tool-set to succeed in their roles.
Additionally, the Company is cultivating sustainable leadership - leaders who will not
only guide the Company now but also chart the course for the future. Key members of the
leadership team graduated from The Global Leadership Program, a nine-month journey curated
in partnership with INSEAD Business School. The program focused on strategic, operational,
leadership and other elements that would equip the nominated leaders for success in the
digital era.
Through market mapping and robust, technology supported talent acquisition practices,
the Company attracts skilled individuals required for operations and business growth. The
Company's Internal Job Posting (IJP) platform provides opportunity for career advancement
to employees and also helps in identification of hidden talent within the organisation.
Employees are encouraged to go for job rotations, move across different areas, functions,
and geographies to build a wholesome experience and increase their capability. This has
resulted in 25% of the Company's vacancies getting filled through internally groomed
talent. Despite a slightly higher Employee attrition, the Company has maintained a 97%
talent availability throughout the year for sustained business operations.
In pursuit of excellence and to build a high-performing culture, the Company has a
meticulously crafted and robust Performance Management System. Through initiatives such as
its esteemed "Applause" program and the prestigious Chairmen's Annual Awards,
the Company celebrates exceptional accomplishments. The culture of appreciation and
recognition is ingrained deep into its DNA. The Company's culture of high performance is
further strengthened by processes like Continuous Feedback, Pay for Performance and Role
Based Promotions. This unleashes the full potential of its employees and drives the
Company towards collaborative success.
Diversity and Inclusion (D&I) plays a crucial role in the Company's business
success. The Company has made significant strides across three key areas of its D&I
strategy: Hiring, Retention, and Cultural inclusivity. The Company's leadership has
embraced an inclusive mindset, welcoming 40+ women this year, which has taken overall
women's representation to 6%. The Company is committed to creating gender-intelligent and
inclusive people managers, and it has introduced a Women Buddy Program to support women in
their professional journey. Furthermore, our 'women apprentices' & 'cadre-building'
program aims to develop female employees from early career stages in manufacturing roles,
preparing them to take on shift supervisor positions.
The Company believes in frequent two way communication to keep the employees abreast of
developments within the organisation and to hear their concerns/suggestions. These are
done through quarterly town halls, newsletters and all employee communication emails.
Safety, Productivity and Cost Efficiency were incorporated in the long-term wage
settlement at Savli.
As a result of the above endeavors, the Company has experienced no instances of labour
unrest or disputes at any of its manufacturing facilities, resulting in 'Zero' production
loss.
VIGIL MECHANISM
Your Company has an established vigil mechanism for Directors and employees to report
their genuine concerns, as approved by the Board on the recommendation of the Audit
Committee.
The Whistle Blower Policy of the Company is formulated and uploaded on the Company's
website at the following https://www.
iubilantingrevia.com/investors/corporate-governance/policies-
and-codes/whistle-blower-policy.
The Policy provides for adequate safeguards against victimisation of employees who
avail of the mechanism and also provides for direct access to the Chairperson of the Audit
Committee. It is affirmed that no personnel of the Company have been denied access to the
Audit Committee.
CORPORATE SOCIAL RESPONSIBILITY ('CSR')
Jubilant Bhatia Foundation ('JBF'), a not-for-profit arm of the Jubilant Bhartia Group
works towards conceptualisation and implementation of CSR activities of Jubilant.
Throughout the year, through CSR, following the 4P (Public-Private-People-Partnership)
model, the Company actively drove community engagement. During FY 2024, the Company's
several community empowering proiects are stated below:
Healthcare: The purpose of this program was to achieve good health and wellbeing,
promote health-seeking behaviour and to provide effective basic healthcare to the
community.
Jubilant Bhartia Foundation ('JBF') is implementing Arogya/ Jubicare program through
Mobile Medical Unit and Jubilant Bhartia Foundation Medical Centre around manufacturing
units of the Company.
The Company, through JBF is also reaching the community through focused awareness
program on nutrition through village level workers.
In line with the national goal of ending TB by 2025, the district administration Amroha
in partnership with JBF has developed an automated interactive voice call response system
(IVRS) for enquiring the daily medicine intake or specific requirement of the patients.
Education: The purpose of this program is strengthening of education and learning
environment in rural areas. The various programs undertaken under this CSR activity are:
Muskaan program for Strengthening Rural Education system through various
education centric programs in government school.
Khushiyon ki Pathshala program to inculcate 21st century value based
skills in rural government primary school student.
Digitisation program in partnership with HP across the location through
E-Muskaan
Setting up of micro science Labs in schools.
Career counselling to support students of government school.
Livelihood: The purpose of this program is creating sustainable livelihood
opportunity for all. Nayee Disha is livelihood centric program. Under this program
vocational training is provided & virtual skills are developed to enhance
employability skills amongst youths & women in the community around manufacturing
units. JubiFarm program empowers the farmers by facilitating access to modern and
sustainable farming methods. Grameen Samriddhi Kendra has been established in Gajraula to
promote entrepreneurship with initial focus on dairy farming.
Rural Development: The purpose of this program is strengthening the services for
the community in the rural areas. The various programs undertaken under this CSR activity
are:
Establishment of Jansuvidha Kendra for the community in rural areas for creating
awareness and also for providing support for easy access to government's social welfare
schemes.
Establishing Jansanchetna Program for emergency preparedness at village level
through Emergency Response Team (ERTs)
A detailed note on Sustainability & CSR Committee is given under 'Corporate
Governance Report'.
Annual Report on CSR for FY 2024 is attached as Annexure-4.
POLICY ON PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE
As per the requirements of the Sexual Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013, the Company has formulated a Policy on Prevention of
Sexual Harassment at Workplace for prevention, prohibition and redressal of sexual
harassment at workplace and an Internal Complaints Committee has also been set up to
redress any such complaints received.
During the year under review, the Company has complied with the provisions relating to
the constitution of Internal Complaints Committee under the Sexual Harassment of Women at
Workplace (Prevention, Prohibition and Redressal) Act, 2013.
The disclosure of complaints in relation to the Sexual Harassment of Women at Workplace
is given under 'Corporate Governance Report'.
OTHER DISCLOSURES
1. Extracts of Annual Return: Pursuant to the provisions of Section 134(3)(a) of
the Act, the annual return for FY 2024 has been uploaded on the Company's website and can
be accessed at https://wwwJubilantingrevia.com/investors/ financials/annual-reports.
2. Public Deposits: The Company has not accepted any deposits from the public
during the year. The Company had no outstanding, overdue, unpaid or unclaimed deposits at
the beginning and end of FY 2024.
3. Loans, Guarantees and Investments: Details of loans, guarantees/ securities
and investments along with the purpose for which the loans, guarantees or securities are
proposed to be utilised by the recipient have been disclosed in note no. 5 and 6 to the
standalone financial statements.
4. Particulars of contracts or arrangements with the Related Parties: The
Company has formulated a policy on Related Party Transactions ('RPTs') for dealing with
the review and approval of RPTs. Prior omnibus approval is obtained for RPTs which are of
repetitive nature. All RPTs are placed before the Audit Committee for review and approval
in terms of the Act and Listing Regulations, as amended.
All RPTs entered into during FY 2024 were in the ordinary course of business and on
arm's length basis. No material RPTs, as defined in the 'Policy on Materiality of Related
Party Transactions and Dealing with Related Party Transaction's' were entered into during
FY 2024 by the Company. Accordingly, the disclosure of RPTs as required under Section
134(3)(h) of the Act in form AOC-2 is not applicable. Your Directors draw attention of the
members to note no. 37 to the standalone financial statements which sets out the Related
Party disclosures.
5. Material Changes in Financial Position: No material change or commitment has
occurred after the close of FY 2024 till the date of this Report, which affects the
financial position of the Company.
6. Orders passed by Courts/ Regulators: No significant or material order has
been passed by the regulators or courts or tribunals impacting the going concern status of
the Company or its future operations.
7. Secretarial Standards: The Company has complied with Secretarial Standards
issued by the Institute of Company Secretaries of India on Meetings of the Board of
Directors and General Meetings.
8. Neither the Managing Director nor the Whole-time Director(s) of the Company received
any remuneration or commission from any of its subsidiaries.
9. During the year under review no proceedings are made or pending under the Insolvency
and Bankruptcy Code, 2016 and there is no instance of one-time settlement with any Bank or
Financial Institution.
CORPORATE GOVERNANCE
As a responsible corporate citizen, the Company is committed to maintain the highest
standards of Corporate Governance and believes in adhering the best corporate practices
prevalent globally.
A detailed Report on Corporate Governance is attached as Annexure-5 and forms
part of this Report. A certificate from a Practicing Company Secretary confirming
compliance with the conditions of Corporate Governance, as stipulated in Clause E of
Schedule V to the Listing Regulations is attached to the Corporate Governance Report.
MANAGEMENT DISCUSSION AND ANALYSIS REPORT
The Management Discussion and Analysis Report on the operations of the Company as
provided under the Listing Regulations has been given separately and forms part of this
Report.
DISCLOSURE BY LARGE CORPORATE IDENTIFIED BASED ON THE ERSTWHILE CRITERIA
In terms of SEBI Circular no. SEBI/HO/DDHS/DDHS-RACPOD1/P/ CIR/2023/172 dated October
19, 2023, the Company is no more falling under the category of Large Corporate (LC)
effective from 1st April, 2024.
However, in terms of above stated circular, the companies identified as LC under
erstwhile criteria shall endeavour to comply with the requirement of raising 25% of their
incremental borrowings done during FY 2022, FY 2023 and FY 2024 respectively by way of
issuance of debt securities till March 31, 2024, failing which, such LCs are required to
provide a one-time explanation in their Annual Report for FY 2024.
During FY 2024, the Company did not find feasible to raise the incremental borrowings
by issuance of debt securities as the interest rate in money market was highly volatile
and was available at higher rate of interest as compare to other fund raising options.
Therefore, during FY 2024, the Company did not raise the incremental borrowings by
issuance of debt securities.
ACKNOWLEDGEMENTS
Your Directors acknowledge their gratitude for the co-operation and assistance received
from the Central and State Government authorities. Your Directors thank the shareholders,
financial institutions, banks/ other lenders, debenture trustees, customers, vendors and
other business associates for the confidence reposed by them in the Company and its
management and look forward to their continued support. The Board also places on record
its appreciation for the dedication and commitment of the Company's employees at all
levels, which has continued to be our major strength and we look forward to their
continued support in the future.
For and on behalf of the Board |
|
Shyam S. Bhartia |
Hari S. Bhartia |
Chairman |
Co - Chairman and Whole - Time Director |
(DIN: 00010484) |
(DIN: 00010499) |
Place: Noida |
|
Date: May 14, 2024 |
|